Please login to the form below

Not currently logged in
Email:
Password:

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

Roche and Atea partner on oral COVID-19 drug development

Swiss pharma giant Roche has partnered with Atea Pharmaceuticals to develop an antiviral oral treatment for COVID-19.

The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19.

According to Roche, AT-527 blocks the viral RNA polymerase enzyme required for viral replication. It is currently being studied in a phase 2 study for the treatment of patients hospitalised with moderate COVID-19.

In the first quarter of 2021, a phase 3 clinical trial is expected to launch testing AT-527 as a potential therapy for COVID-19 patients outside a hospital setting. The drug could also be developed for the post-exposure prophylactic settings, added Roche.

In August, Roche also partnered with Regeneron to bolster manufacturing and global development capabilities for the latter’s investigational antibody cocktail for COVID-19.

Under the terms of the deal, Roche and Regeneron will jointly fund and execute the ongoing phase 3 prevention trials of the drug, REGN-COV2, as well as further phase 1 studies in healthy volunteers.

Roche’s existing rheumatoid arthritis drug Actemra (tocilizumab) is also being studied in combination with Gilead’s antiviral remdesivir in hospitalised patients with severe COVID-19 pneumonia in the REMDACTA trial.

UK selects Oxford Immunotec to supply T cell testing for COVID-19 vaccines

The UK Vaccine Taskforce has partnered with Oxford Immunotec to supply T cell testing for its assessment of potential COVID-19 vaccine candidates.

Oxford Immunotec will use its T-SPOT technology to measure the magnitude of the SARS-CoV-2 protein-specific T cell response of different vaccine candidates.

T cell immunity is believed to play a key role in the body’s protection against infection from the SARS-CoV-2 virus, which causes COVID-19.

The UK Vaccines Taskforce is currently including T cell analysis in COVID-19 vaccine trials, as it is believed this could indicate longer-term immunity compared to antibodies.

"The UK Vaccines Taskforce is delighted to be partnering Oxford Immunotec, an experienced team who are responsible for running the Vaccines Taskforce T cell tests to assess the immunogenicity of COVID-19 vaccines,” said Kate Bingham, chair of the UK government’s Vaccines Taskforce.

“It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons,” she added.

Article by
Lucy Parsons

22nd October 2020

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....